XML 25 R5.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statement of Changes in Shareholders’ Equity (capital Deficiency) - USD ($)
$ in Thousands
Ordinary shares
Additional paid-in capital
Accumulated other comprehensive deficit
Accumulated deficit
Total
Balance at Dec. 31, 2018 $ 58 $ 11,596 $ (18,038) $ (6,384)
Balance (in Shares) at Dec. 31, 2018 21,924,208        
Issuance of ordinary shares and warrants, net of issuance costs $ 16 14,022   14,038
Issuance of ordinary shares and warrants, net of issuance costs (in Shares) 4,762,656        
Issuance of ordinary shares to employees and non-employees upon exercise of warrants $ 1 136   137
Issuance of ordinary shares to employees and non-employees upon exercise of warrants (in Shares) 454,166        
Issuance of ordinary shares to investors upon exercise of warrants 25   25
Issuance of ordinary shares to investors upon exercise of warrants (in Shares) [1] 9,050        
Share-based compensation 16,245   16,245
Additional consideration with respect to an assets purchase agreement, see note 9a (10,276)   (10,276)
Net loss for the year   (22,563) (22,563)
Balance at Dec. 31, 2019 $ 75 31,748 (40,601) (8,778)
Balance (in Shares) at Dec. 31, 2019 27,150,080        
Issuance of ordinary shares and warrants, net of issuance costs $ 14 70,999   71,013
Issuance of ordinary shares and warrants, net of issuance costs (in Shares) 4,624,500        
Initial public offering of ordinary shares, net of offering costs $ 31 169,136   169,167
Initial public offering of ordinary shares, net of offering costs (in Shares) 10,555,556        
Issuance of ordinary shares to employees and non-employees upon exercise of warrants $ 3 497   500
Issuance of ordinary shares to employees and non-employees upon exercise of warrants (in Shares) 997,863        
Issuance of ordinary shares to investors upon exercise of warrants $ 5 125   130
Issuance of ordinary shares to investors upon exercise of warrants (in Shares) 1,662,929        
Share-based compensation 24,781   24,781
Conversion of related party liability to shareholders’ equity, see note 9a $ 3 17,745   17,748
Conversion of related party liability to shareholders’ equity, see note 9a (in Shares) 1,109,245        
Net loss for the year       (43,815) (43,815)
Balance at Dec. 31, 2020 $ 131 315,031 (84,416) 230,746
Balance (in Shares) at Dec. 31, 2020 46,100,173        
Issuance of ordinary shares upon exercise of warrants $ 2 265 267
Issuance of ordinary shares upon exercise of warrants (in Shares) 780,920        
Issuance of ordinary shares to employees and non-employees upon exercise of options $ 3 3,330 3,333
Issuance of ordinary shares to employees and non-employees upon exercise of options (in Shares) 1,099,946        
Issuance of ordinary shares due to business combination and assets acquisition (refer to Note 3) $ 13 101,497 101,510
Issuance of ordinary shares due to business combination and assets acquisition (refer to Note 3) (in Shares) 3,810,402        
Share-based compensation 18,697 18,697
Unrealized loss from available- for-sale securities     (607) (607)
Net loss for the year (61,798) (61,798)
Balance at Dec. 31, 2021 $ 149 $ 438,820 $ (607) $ (146,214) $ 292,148
Balance (in Shares) at Dec. 31, 2021 51,791,441        
[1] Less than 1 thousand US dollars.